Spirulina and pulmonary hypertension.

PAH pathophysiology

• Endothelial dysfunction:Healthy pulmonary endothelial cells produce NO (eNOS) and prostacyclin (COX-2) to maintain vasodilation, and inhibit smooth muscle proliferation. In PAH, eNOS is uncoupled (producing superoxide instead of NO), prostacyclin synthase is reduced, and endothelin-1 is massively upregulated. The net result: vasoconstriction, smooth muscle hypertrophy, and intimal remodelling progressively obliterating pulmonary arteries.
• NADPH oxidase in PAH endothelium:NOX2 and NOX4 are both upregulated in PAH pulmonary arterial endothelial and smooth muscle cells. Superoxide from NOX2 scavenges NO, producing peroxynitrite (ONOO–) that uncouples eNOS further — a self-amplifying cycle. NOX4-derived H₂O₂stimulates smooth muscle proliferation. Phycocyanobilin addresses the NOX2 component of this cycle.
• Endothelin-1:ET-1 is the most potent endogenous vasoconstrictor. In PAH, ET-1 is elevated 5–10-fold in pulmonary arterial blood. ET-1 activates ETA and ETB receptors on smooth muscle (vasoconstriction, proliferation) and fibroblasts (fibrosis). NF-κB drives ET-1 gene transcription — phycocyanobilin’s NF-κB inhibition reduces ET-1 production upstream of receptor activation.
• Classification:Group 1 PAH (idiopathic, heritable, drug-induced, connective tissue disease-associated) is the highest-risk group. Group 2 (left heart disease), Group 3 (lung disease and hypoxia), Group 4 (chronic thromboembolic pulmonary hypertension, CTEPH), and Group 5 (miscellaneous) have different management and supplement contexts.

PAH-targeted therapies: interaction context

Endothelin receptor antagonists (ERAs)

• Bosentan (ETA/ETB dual antagonist), ambrisentan (ETA selective), and macitentan (long-acting dual) are standard PAH therapy. They are metabolised by CYP3A4/CYP2C9 (bosentan induces both). No documented spirulina pharmacokinetic interaction. Phycocyanobilin’s NF-κB-mediated ET-1 suppression is upstream and complementary to receptor blockade by ERAs — mechanistically synergistic (less ET-1 produced + blocked at receptor). This is a genuinely additive anti-endothelin effect.

Phosphodiesterase-5 inhibitors

• Sildenafil and tadalafil inhibit cGMP breakdown, amplifying the effect of whatever pulmonary NO is available. Combined with spirulina’s NO preservation (less NO scavenged by NOX2 superoxide), the combination is mechanistically synergistic. More NO is preserved by phycocyanobilin; more cGMP is maintained by PDE5 inhibition. The theoretical risk is excessive pulmonary vasodilation — but this is the treatment goal in PAH and is already managed by titrating sildenafil/tadalafil dose. Discuss combination with the PAH specialist.

Soluble guanylate cyclase stimulators

• Riociguat directly stimulates soluble guanylate cyclase (sGC), increasing cGMP independent of NO. Combined with spirulina’s NO preservation, both cGMP amplification pathways are enhanced. Riociguat is used in CTEPH and PAH; it cannot be combined with PDE5 inhibitors (hypotension risk). The spirulina combination at standard doses is unlikely to cause additive hypotension — but given the narrow therapeutic margin in PAH, inform the specialist.

Prostacyclin analogues

• Epoprostenol (IV), treprostinil (IV/SC/inhaled), and iloprost (inhaled) are used in severe PAH. Spirulina’s GLA/DGLA pathway reduces thromboxane A₂(a pulmonary vasoconstrictor) by competing at COX — complementary to prostacyclin supplementation. No pharmacokinetic interaction.

Anaemia in PAH

• Iron deficiency is disproportionately prevalent in PAH and worsens exercise capacity, functional class, and prognosis independently. Iron is required for mitochondrial Complex I/III function and for eNOS BH4 cofactor synthesis. Iron correction improves PAH outcomes.
• IV iron is preferred for correction in PAH (oral iron poorly absorbed in gut congestion from right heart failure). Spirulina iron is a modest nutritional contribution — not a therapeutic iron source for established iron-deficiency in PAH. Discuss iron supplementation strategy with the PAH team.

Practical guidance

• PAH is a serious, progressive condition — all supplement decisions require explicit discussion with the PAH specialist or pulmonologist before starting
• The NO-preserving and endothelin-1-reducing mechanisms are directly relevant and mechanistically complementary to standard PAH-targeted therapies
• 3–5 g/day if cleared by specialist; cold format for full phycocyanin
• Monitor for signs of excessive vasodilation (increased light-headedness, hypotension) particularly if on PDE5 inhibitors
• Iron deficiency correction in PAH requires IV iron — spirulina iron alone is insufficient for therapeutic correction